Commercial Insight - Inflammatory Bowel Disease - Convenience and compliance drive market success
Commercial Insight - Inflammatory Bowel Disease - Convenience and compliance drive market success - Companies and Markets adds new report
© companiesandmarkets.com
26.11.2008 08:49:02 Commercial Insight - Inflammatory Bowel Disease - Convenience and compliance drive market success - a new market research report on www.companiesandmarkets.com
(live-PR.com) - www.companiesandmarkets.com/Summary-Market-Repor ..
Introduction
Several product launches and indication expansion caused substantial sales growth in the seven major inflammatory bowel disease markets from $1.7 billion in 2004 to $2.7 billion in 2007. Datamonitor forecasts the IBD market will grow with a CAGR (200717) of 4.6% to reach $4 billion in 2017 and success will depend on brands demonstrating patient convenience and improved compliance.
Scope
*In-depth analysis
of the current and future inflammatory bowel disease market across the US, 5 EU and Japanese markets, and a rest of world snapshot
*Crohn´s disease and ulcerative colitis specific sales forecasts for key brands to 2017, with total brand figures to benchmark IBD sales against
*Provides detailed brand dynamics discussion, including analysis of the anti-TNFs Remicade, Humira, Cimzia and impact of new products such as Tysabri
*Assess the strategies of the key developers in the IBD market
Highlights
Anti-TNF sales will peak at over $2 billion in 2012 because of earlier use, extension into ulcerative colitis, uptake of Cimzia (certolizumab) and the launch of golimumab (CNTO-148). Despite competitive pressure from novel agents and biosimilars, the TNF inhibitors will generate $1.8 billion in IBD indications in 2017 and retain market dominance.
Cimzia is the third anti-TNF for Crohn´s disease, but with few perceived advantages, it will remain a third-line therapy. Time on the market, method of delivery and patient preference will increasingly determine anti-TNF choice. Humira will attain market and class leadership from Remicade by 2014, achieving IBD sales of $0.8 billion by 2017.
Patient convenience/compliance will drive brand choice in the homogenous 5-ASA class. Lialda reduces pill burden and data indicate superiority to Asacol. With its favorable once-daily dosing, Lialda is set to head the 5-ASA class and smart marketing will minimize Pentasa cannibalization. Lialda will generate total brand sales of over $400 m in 2017
Reasons to Purchase
*Quantify the current size of IBD sales in the seven major markets and understand trends in the rest of the world
*Assess the impact of events, such as biosimilars entry, on sales of over 30 key brand name products
*Understand the IBD patient acquisition process as well as specific market opportunities and threats
www.companiesandmarkets.com/Summary-Market-Repor ..
Introduction
Several product launches and indication expansion caused substantial sales growth in the seven major inflammatory bowel disease markets from $1.7 billion in 2004 to $2.7 billion in 2007. Datamonitor forecasts the IBD market will grow with a CAGR (200717) of 4.6% to reach $4 billion in 2017 and success will depend on brands demonstrating patient convenience and improved compliance.
Scope
*In-depth analysis
|
|
*Crohn´s disease and ulcerative colitis specific sales forecasts for key brands to 2017, with total brand figures to benchmark IBD sales against
*Provides detailed brand dynamics discussion, including analysis of the anti-TNFs Remicade, Humira, Cimzia and impact of new products such as Tysabri
*Assess the strategies of the key developers in the IBD market
Highlights
Anti-TNF sales will peak at over $2 billion in 2012 because of earlier use, extension into ulcerative colitis, uptake of Cimzia (certolizumab) and the launch of golimumab (CNTO-148). Despite competitive pressure from novel agents and biosimilars, the TNF inhibitors will generate $1.8 billion in IBD indications in 2017 and retain market dominance.
Cimzia is the third anti-TNF for Crohn´s disease, but with few perceived advantages, it will remain a third-line therapy. Time on the market, method of delivery and patient preference will increasingly determine anti-TNF choice. Humira will attain market and class leadership from Remicade by 2014, achieving IBD sales of $0.8 billion by 2017.
Patient convenience/compliance will drive brand choice in the homogenous 5-ASA class. Lialda reduces pill burden and data indicate superiority to Asacol. With its favorable once-daily dosing, Lialda is set to head the 5-ASA class and smart marketing will minimize Pentasa cannibalization. Lialda will generate total brand sales of over $400 m in 2017
Reasons to Purchase
*Quantify the current size of IBD sales in the seven major markets and understand trends in the rest of the world
*Assess the impact of events, such as biosimilars entry, on sales of over 30 key brand name products
*Understand the IBD patient acquisition process as well as specific market opportunities and threats
www.companiesandmarkets.com/Summary-Market-Repor ..
| Author: |
